Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Nivolumab + Vidutolimod|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Nivolumab||Opdivo||MDX-1106|BMS-936558||Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 86||Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) in patients with melanoma, renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, in combination with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent NSCLC without EGFR or ALK alterations, in combination with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, in combination with Cabometyx (cabozantinib) in patients with advanced renal cell carcinoma, and in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (FDA.gov).|
|Vidutolimod||CMP-001|CYT003|CYT 003|CYT-003|ARB-1598|QbG10||TLR9 Agonist 8||Vidutolimod (CMP-001) is a Toll-like receptor 9 (TLR-9) agonist that may enhance the TH1-mediated immune response (PMID: 23384679).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05445609||Phase II||Nivolumab + Vidutolimod||Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer||Not yet recruiting||USA||0|
|NCT03618641||Phase II||Nivolumab + Vidutolimod||CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease||Active, not recruiting||USA||0|
|NCT04401995||Phase II||Nivolumab Nivolumab + Vidutolimod||Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab||Recruiting||USA||0|
|NCT04698187||Phase II||Nivolumab + Vidutolimod||CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma||Active, not recruiting||USA||0|
|NCT04695977||Phase II||Nivolumab Nivolumab + Vidutolimod||CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma||Active, not recruiting||USA||0|